LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Zandee, Wouter"
  2. AU=Seimon Tracie A AU=Seimon Tracie A
  3. AU="Jonathan Izudi"

Suchergebnis

Treffer 1 - 10 von insgesamt 36

Suchoptionen

  1. Artikel ; Online: Letter to the Editor From Zandee and Links: "Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for

    Zandee, Wouter T / Links, Thera P

    Journal of the Endocrine Society

    2023  Band 7, Heft 3, Seite(n) bvad004

    Sprache Englisch
    Erscheinungsdatum 2023-01-25
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2472-1972
    ISSN (online) 2472-1972
    DOI 10.1210/jendso/bvad004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel ; Online: Should everolimus be stopped after radiological progression in metastatic insulinoma? A "pro" point of view.

    Zandee, Wouter T / Hofland, Johannes / de Herder, Wouter W

    Endocrine

    2021  Band 71, Heft 1, Seite(n) 256–257

    Mesh-Begriff(e) Everolimus/therapeutic use ; Humans ; Hypoglycemia ; Insulinoma/diagnostic imaging ; Pancreatic Neoplasms/diagnostic imaging ; Pancreatic Neoplasms/drug therapy ; Sirolimus
    Chemische Substanzen Everolimus (9HW64Q8G6G) ; Sirolimus (W36ZG6FT64)
    Sprache Englisch
    Erscheinungsdatum 2021-01-04
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 1194484-5
    ISSN 1559-0100 ; 1355-008X ; 0969-711X
    ISSN (online) 1559-0100
    ISSN 1355-008X ; 0969-711X
    DOI 10.1007/s12020-020-02570-4
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3884: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Role of biomarker tests for diagnosis of neuroendocrine tumours.

    Hofland, Johannes / Zandee, Wouter T / de Herder, Wouter W

    Nature reviews. Endocrinology

    2018  Band 14, Heft 11, Seite(n) 656–669

    Abstract: Neuroendocrine tumours (NETs) are neoplasms that arise from neuroendocrine cells. Neuroendocrine cells and their tumours can secrete a wide range of amines and polypeptide hormones into the systemic circulation. This feature has triggered widespread ... ...

    Abstract Neuroendocrine tumours (NETs) are neoplasms that arise from neuroendocrine cells. Neuroendocrine cells and their tumours can secrete a wide range of amines and polypeptide hormones into the systemic circulation. This feature has triggered widespread investigation into circulating biomarkers for the diagnosis of NETs as well as for the prediction of the biological behaviour of tumour cells. Classic examples of circulating biomarkers for gastroenteropancreatic NETs include chromogranin A, neuron-specific enolase and pancreatic polypeptide as well as hormones that elicit clinical syndromes, such as serotonin and its metabolites, insulin, glucagon and gastrin. Biomarker metrics of general markers for diagnosing all gastroenteropancreatic NET subtypes are limited, but specific hormonal measurements can be of diagnostic value in select cases. In the past decade, methods for detecting circulating transcripts and tumour cells have been developed to improve the diagnosis of patients with NETs. Concurrently, modern scanning techniques and superior radiotracers for functional imaging have markedly expanded the options for clinicians dealing with NETs. Here, we review the latest research on biomarkers in the NET field to provide clinicians with a comprehensive overview of relevant diagnostic biomarkers that can be implemented in dedicated situations.
    Mesh-Begriff(e) Biomarkers/blood ; Cells, Cultured ; Chromogranin A/blood ; Female ; Glucagon/blood ; Humans ; Intestinal Neoplasms/blood ; Intestinal Neoplasms/diagnosis ; Male ; Middle Aged ; Neuroendocrine Cells/metabolism ; Neuroendocrine Tumors/blood ; Neuroendocrine Tumors/diagnosis ; Neuroendocrine Tumors/diagnostic imaging ; Pancreatic Neoplasms/blood ; Pancreatic Neoplasms/diagnosis ; Pancreatic Polypeptide/blood ; Protein Precursors/blood ; Sensitivity and Specificity ; Stomach Neoplasms/blood ; Stomach Neoplasms/diagnosis ; Tomography, Emission-Computed, Single-Photon/methods
    Chemische Substanzen Biomarkers ; Chromogranin A ; PPY protein, human ; Protein Precursors ; Pancreatic Polypeptide (59763-91-6) ; Glucagon (9007-92-5)
    Sprache Englisch
    Erscheinungsdatum 2018-08-29
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2489381-X
    ISSN 1759-5037 ; 1759-5029
    ISSN (online) 1759-5037
    ISSN 1759-5029
    DOI 10.1038/s41574-018-0082-5
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6336: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 93: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines.

    Zandee, Wouter T / de Herder, Wouter W

    Neuroendocrinology

    2018  Band 106, Heft 4, Seite(n) 357–365

    Abstract: In 2016, the third version of guidelines for the diagnosis and treatment of neuroendocrine tumors (NETs) has been published by the European Neuroendocrine Tumor Society (ENETS). These guidelines reflect the progress in treatment of NETs, and by comparing ...

    Abstract In 2016, the third version of guidelines for the diagnosis and treatment of neuroendocrine tumors (NETs) has been published by the European Neuroendocrine Tumor Society (ENETS). These guidelines reflect the progress in treatment of NETs, and by comparing the newest guidelines with the first guidelines of 2001, this progress can be clearly recognized. Diagnostic accuracy has been increased by the introduction of PET-CT with Ga-labelled somatostatin analogs, and multiple new treatments and treatment schedules have been developed, like peptide receptor radiotherapy with radiolabeled somatostatin analogs, or targeted therapies. Evidence and indications for these therapies are discussed in the ENETS guidelines. In this review, we aim to show the progress in NET diagnosis and treatment on the basis of the advances in the guidelines, but also to discuss the unsolved questions and unmet needs which still remain.
    Mesh-Begriff(e) Humans ; Neuroendocrine Tumors/diagnosis ; Neuroendocrine Tumors/therapy ; Practice Guidelines as Topic
    Sprache Englisch
    Erscheinungsdatum 2018-01-10
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 123303-8
    ISSN 1423-0194 ; 0028-3835
    ISSN (online) 1423-0194
    ISSN 0028-3835
    DOI 10.1159/000486096
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 531: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres.

    Zandee, Wouter T / Merola, Elettra / Poczkaj, Karolina / de Mestier, Louis / Klümpen, Heinz-Josef / Geboes, Karen / de Herder, Wouter W / Munir, Alia

    European journal of cancer care

    2022  Band 31, Heft 6, Seite(n) e13639

    Abstract: Objective: To evaluate the impact of multidisciplinary team (MDT) meetings on the management of patients with neuroendocrine neoplasms (NENs).: Methods: All newly referred gastro-entero-pancreatic (GEP)-NEN patients discussed from 1 April to 1 ... ...

    Abstract Objective: To evaluate the impact of multidisciplinary team (MDT) meetings on the management of patients with neuroendocrine neoplasms (NENs).
    Methods: All newly referred gastro-entero-pancreatic (GEP)-NEN patients discussed from 1 April to 1 October 2017 in the MDT of seven European expert centres were prospectively included. The impact on patients' management was defined as a change in diagnosis, grade, stage or treatment.
    Results: A total of 292 patients were included, mainly small intestinal (siNENs) (32%) and pancreatic NENs (28%), with distant metastases in 51%. Patients had received prior surgery in 43% of cases and prior medical treatment in 32%. A significant change occurred in 61% of NENs: 7% changes in diagnosis, 8% in grade and 16% in stage. The MDT recommended a new treatment for 51% of patients, mainly surgery (9%) or somatostatin analogues (20%). A significant change was most frequently observed in patients with Stage IV disease (hazard ratio [HR] 3.6, 95% confidence interval [CI]: 1.9-6.9 vs. Stage I) and G2 NENs (vs. G1, HR 2.1 95% CI: 1.2-3.8).
    Conclusion: NEN-dedicated MDT discussion in expert centres yields significant management changes in over 60% of patients and thus represents the gold standard for the management of these patients.
    Mesh-Begriff(e) Humans ; Intestinal Neoplasms/therapy ; Pancreatic Neoplasms/therapy ; Pancreatic Neoplasms/pathology ; Neuroendocrine Tumors/therapy ; Disease-Free Survival ; Patient Care Team ; Stomach Neoplasms/therapy
    Sprache Englisch
    Erscheinungsdatum 2022-06-23
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1303114-4
    ISSN 1365-2354 ; 0961-5423 ; 1360-5801
    ISSN (online) 1365-2354
    ISSN 0961-5423 ; 1360-5801
    DOI 10.1111/ecc.13639
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3347: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel: Cardiovascular effects of overt and subclinical hyperthyroidism: focus on differentiated thyroid cancer.

    Links, Thera P / van der Boom, Trynke / Zandee, Wouter T / Lefrandt, Joop D

    Endocrine connections

    2020  Band 10, Heft 1, Seite(n) R43–R51

    Abstract: Thyroid hormone stimulates cardiac inotropy and chronotropy via direct genomic and non-genomic mechanisms. Hyperthyroidism magnifies these effects, resulting in an increase in heart rate, ejection fraction and blood volume. Hyperthyroidism also affects ... ...

    Abstract Thyroid hormone stimulates cardiac inotropy and chronotropy via direct genomic and non-genomic mechanisms. Hyperthyroidism magnifies these effects, resulting in an increase in heart rate, ejection fraction and blood volume. Hyperthyroidism also affects thrombogenesis and this may be linked to a probable tendency toward thrombosis in patients with hyperthyroidism. Patients with hyperthyroidism are therefore at higher risk for atrial fibrillation, heart failure and cardiovascular mortality. Similarly, TSH suppressive therapy for differentiated thyroid cancer is associated with increased cardiovascular risk. In this review, we present the latest insights on the cardiac effects of thyroid suppression therapy for the treatment of thyroid cancer. Finally, we will show new clinical data on how to implement this knowledge into the clinical practice of preventive medicine.
    Sprache Englisch
    Erscheinungsdatum 2020-12-14
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2668428-7
    ISSN 2049-3614
    ISSN 2049-3614
    DOI 10.1530/EC-20-0539
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?

    Zandee, Wouter T / de Herder, Wouter W / Jann, Henning

    The Lancet. Oncology

    2017  Band 18, Heft 6, Seite(n) e299

    Mesh-Begriff(e) Carcinoid Tumor ; Humans ; Incidence ; Malignant Carcinoid Syndrome ; Prognosis ; Tumor Burden
    Sprache Englisch
    Erscheinungsdatum 2017
    Erscheinungsland England
    Dokumenttyp Letter ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(17)30335-2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5696: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.

    Zandee, Wouter T / Brabander, Tessa / Blažević, Anela / Minczeles, Noémie S / Feelders, Richard A / de Herder, Wouter W / Hofland, Johannes

    The Journal of clinical endocrinology and metabolism

    2021  Band 106, Heft 9, Seite(n) e3665–e3672

    Abstract: Context: Peptide receptor radionuclide therapy (PRRT) with [Lutetium-177-DOTA0-Tyr3]octreotate (177Lu-DOTATATE) results in an increase of progression-free survival and quality of life in patients with progressive, well-differentiated neuroendocrine ... ...

    Abstract Context: Peptide receptor radionuclide therapy (PRRT) with [Lutetium-177-DOTA0-Tyr3]octreotate (177Lu-DOTATATE) results in an increase of progression-free survival and quality of life in patients with progressive, well-differentiated neuroendocrine neoplasms (NENs).
    Objective: To study the effect of 177Lu-DOTATATE in patients with carcinoid syndrome and radiologically stable or newly diagnosed disease treated solely for the purpose of symptom reduction.
    Design: Retrospective cohort study.
    Setting: Tertiary care hospital.
    Patients: Twenty-two patients with a metastatic midgut NEN, elevated urinary 5-hydroxyindolacetic acid excretion, and flushing and/or diarrhea despite treatment with a somatostatin analog, without documented disease progression.
    Intervention: PRRT with 177Lu-DOTATATE (intended cumulative dose: 29.6 GBq) with a primary aim to reduce symptoms.
    Results: After PRRT, mean bowel movement frequency (BMF) decreased from 6.1 ± 3.4 to 4.6 ± 3.6 per day (P = 0.009). Flushes decreased from 4.3 ± 2.9 to 2.4 ± 2.7 flushes per day (P = 0.002). A decrease of BMF of more than 30% occurred in 47% of patients with baseline BMF of 4 or more (n = 17). In patients with ≥2 episodes of flushing a day (n = 15), 67% of patients had more than 50% decrease of daily flushing. A decrease in urinary 5-hydroxyindolacetic acid excretion of more than 30% was seen in 56% of patients. The European Organization for Research and Treatment of Cancer-Core Module diarrhea subscale score showed a trend toward improvement by an average of 16.7 ± 33.3 points (P = 0.11).
    Conclusion: PRRT with 177Lu-DOTATATE effectively reduced diarrhea and flushing in patients with carcinoid syndrome and can be considered for symptomatic treatment of carcinoid syndrome insufficiently controlled with somatostatin analogs.
    Mesh-Begriff(e) Aged ; Aged, 80 and over ; Cohort Studies ; Diarrhea/etiology ; Diarrhea/radiotherapy ; Drug Resistance, Neoplasm ; Female ; Humans ; Hydroxyindoleacetic Acid/urine ; Male ; Malignant Carcinoid Syndrome/radiotherapy ; Middle Aged ; Neuroendocrine Tumors/radiotherapy ; Octreotide/analogs & derivatives ; Octreotide/therapeutic use ; Organometallic Compounds/therapeutic use ; Positron Emission Tomography Computed Tomography ; Progression-Free Survival ; Quality of Life ; Radioisotopes/therapeutic use ; Receptors, Peptide/drug effects ; Retrospective Studies ; Somatostatin/analogs & derivatives ; Somatostatin/therapeutic use ; Treatment Outcome
    Chemische Substanzen Organometallic Compounds ; Radioisotopes ; Receptors, Peptide ; Somatostatin (51110-01-1) ; Hydroxyindoleacetic Acid (54-16-0) ; lutetium Lu 177 dotatate (AE221IM3BB) ; Octreotide (RWM8CCW8GP)
    Sprache Englisch
    Erscheinungsdatum 2021-04-30
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgab289
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh III Zs.134: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel ; Online: Management of carcinoid syndrome: a systematic review and meta-analysis.

    Hofland, Johannes / Herrera-Martínez, Aura D / Zandee, Wouter T / de Herder, Wouter W

    Endocrine-related cancer

    2019  Band 26, Heft 3, Seite(n) R145–R156

    Abstract: Carcinoid syndrome (CS) is a debilitating disease caused by functional neuroendocrine tumors. Several treatment options are available to alleviate the hormonal symptoms, but their relative efficacy is unknown. Online databases were searched for ... ...

    Abstract Carcinoid syndrome (CS) is a debilitating disease caused by functional neuroendocrine tumors. Several treatment options are available to alleviate the hormonal symptoms, but their relative efficacy is unknown. Online databases were searched for publications on the treatment of CS symptoms. Independent reviewers assessed relevant publications for study quality and outcome. Meta-analysis of the outcomes of the intervention on CS-related symptoms was stratified by the type of treatment. We found 3682 therapeutic interventions on CS-specific outcomes were collected from 93 studies. Overall, the study qualities were poor with only six randomized controlled clinical trials. The somatostatin analogs octreotide and lanreotide induced symptomatic improvement in 65-72% and biochemical response in 45-46% of patients. An increase in dose or frequency or interclass switch led to a reduction of flushes and/or diarrhea in 72-84% of cases. Retrospective, institutional series showed that liver-directed therapy can improve symptoms in 82% of CS patients with a liver-dominant disease. The serotonin synthesis inhibitor telotristat ethyl reduced bowel movements in 40% of patients with diarrhea refractory to somatostatin analogs. Interferon-alpha controlled CS symptoms in 45-63% of cases. Favorable response has been noted after radionuclide therapy in subgroup analyses of studies not specifically involving CS patients. Chemotherapy and everolimus did not induce a significant response in the CS. We conclude that several treatment lines can be offered to patients suffering from the carcinoid syndrome. Initiation of randomized controlled trials with a primary outcome on carcinoid syndrome symptoms is strongly recommended.
    Mesh-Begriff(e) Female ; Humans ; Male ; Malignant Carcinoid Syndrome/drug therapy ; Neuroendocrine Tumors/drug therapy ; Treatment Outcome
    Sprache Englisch
    Erscheinungsdatum 2019-01-03
    Erscheinungsland England
    Dokumenttyp Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 1218450-0
    ISSN 1479-6821 ; 1351-0088
    ISSN (online) 1479-6821
    ISSN 1351-0088
    DOI 10.1530/ERC-18-0495
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4192: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel: The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines

    Zandee, Wouter T. / de Herder, Wouter W.

    Neuroendocrinology

    2018  Band 106, Heft 4, Seite(n) 357–365

    Abstract: In 2016, the third version of guidelines for the diagnosis and treatment of neuroendocrine tumors (NETs) has been published by the European Neuroendocrine Tumor Society (ENETS). These guidelines reflect the progress in treatment of NETs, and by comparing ...

    Körperschaft Endocrinology Sector, Department of Internal Medicine, ENETS Centre of Excellence, Erasmus MC and Erasmus MC Cancer Institute, Rotterdam, the Netherlands
    Abstract In 2016, the third version of guidelines for the diagnosis and treatment of neuroendocrine tumors (NETs) has been published by the European Neuroendocrine Tumor Society (ENETS). These guidelines reflect the progress in treatment of NETs, and by comparing the newest guidelines with the first guidelines of 2001, this progress can be clearly recognized. Diagnostic accuracy has been increased by the introduction of PET-CT with Ga-labelled somatostatin analogs, and multiple new treatments and treatment schedules have been developed, like peptide receptor radiotherapy with radiolabeled somatostatin analogs, or targeted therapies. Evidence and indications for these therapies are discussed in the ENETS guidelines. In this review, we aim to show the progress in NET diagnosis and treatment on the basis of the advances in the guidelines, but also to discuss the unsolved questions and unmet needs which still remain.
    Schlagwörter Neuroendocrine tumor ; First-/second-line treatment ; ENETS Guidelines
    Sprache Englisch
    Erscheinungsdatum 2018-01-10
    Verlag S. Karger AG
    Erscheinungsort Basel, Switzerland
    Dokumenttyp Artikel
    Anmerkung At the Cutting Edge ; This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
    ZDB-ID 123303-8
    ISSN 1423-0194 ; 0028-3835
    ISSN (online) 1423-0194
    ISSN 0028-3835
    DOI 10.1159/000486096
    Datenquelle Karger Verlag

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 531: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang